Boston Pharmaceuticals: A New Model To De-Risk Drugs

Christopher Viebacher's new venture Boston Pharmaceuticals was established with enough capital - $600 million - to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 early-stage drug candidates that it will attempt to de-risk then sell or license to interested partners